Conferences - Results from #9580

ASCO 2017: PSA doubling time and proximal PSA value predict metastasis-free survival in men with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy June 6, 2017

ASCO 2017: Association of risk of clinical recurrence and prostate cancer death with a 17-gene genomic prostate score value June 6, 2017

ASCO 2017: Development and external validation of a novel risk score to identify insignificant prostate cancer June 6, 2017

ASCO 2017: Emerging Biomarkers of Chemotherapy Resistance June 6, 2017

ASCO 2017: Clinical Implications of Genomic Sequencing in Prostate Cancer June 6, 2017

ASCO 2017: Serum androgens and survival in metastatic castration resistant prostate cancer patients treated with docetaxel and prednisone: Results from CALGB 90401 (Alliance) June 6, 2017

ASCO 2017: History of PSA Screening on Prostate Cancer Aggressiveness June 6, 2017

ASCO 2017: P53 status in primary tumor predicts efficacy of first-line abiraterone and enzalutamide in castration-resistant prostate cancer patients June 6, 2017

ASCO 2017: A 17-gene panel for prediction of adverse surgical pathology in the setting of MRI-guided prostate biopsy June 6, 2017

ASCO 2017: Association of loss of tumor suppressor ZFP36 with lethal prostate cancer June 6, 2017

ASCO 2017: Association of androgen receptor status in plasma DNA with outcome on enzalutamide or abiraterone or castration resistant prostate cancer June 6, 2017

ASCO 2017: Ten-year overall and prostate cancer specific mortality in high-risk patients after high-dose-rate brachytherapy combined with external beam radiation therapy (HDR-BT/EBRT) compared with EBRT alone June 6, 2017

ASCO 2017: Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer June 6, 2017

ASCO 2017: Whole blood androgen receptor variant expression and overall survival in metastatic castrate resistant prostate cancer June 6, 2017

ASCO 2017: Astellas and Seattle Genetics Announce Updated Enfortumab Vedotin Phase 1 Data in Metastatic Urothelial Cancer June 6, 2017

ASCO 2017: The plasma lipidome in castration-resistant prostate cancer June 6, 2017

ASCO 2017: Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC) June 6, 2017

ASCO 2017: Incidence of intrathoracic metastases detected by 68Ga-PSMA-11 PET in early stage prostate cancer June 6, 2017

ASCO 2017: Clinical implications of the 2012 US Preventive Services Task Force PSA screening recommendation in prostate cancer diagnoses and 5-year survival at a Minnesota safety net health care system June 6, 2017

ASCO 2017: Circulating tumour cells and survival in abiraterone and enzalutamide treated patients with castration-resistant prostate cancer June 6, 2017

Page 480 of 616